Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:NDRM

NeuroDerm Ltd. - Ordinary Share (NDRM) Stock Price, News & Analysis

NeuroDerm Ltd. - Ordinary Share logo

About NeuroDerm Ltd. - Ordinary Share Stock (NASDAQ:NDRM)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$38.85
$38.85
50-Day Range
N/A
52-Week Range
$15.20
$38.95
Volume
N/A
Average Volume
418,712 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson's disease, as well as other CNS diseases. The Company's Parkinson's disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages. Its liquid LD/CD and apomorphine formulations include ND0612H, ND0612L and ND0701. It is developing ND0612H for the treatment of patients suffering from severe Parkinson's disease. It is developing ND0612L for the treatment of patients at the moderate stage of Parkinson's disease that can no longer control motor complications with oral levodopa. It has also designed ND0701, which is an apomorphine-based product. ND0701 is for patients suffering from Parkinson's disease, may be used mostly by patients suffering from high motor fluctuations and not responding well to LD/CD.

Remove Ads
Receive NDRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroDerm Ltd. - Ordinary Share and its competitors with MarketBeat's FREE daily newsletter.

NDRM Stock News Headlines

Native Mineral Resources to Issue New Shares
NFT Ltd. - Ordinary Shares-Class A
Lying in hospital… staring at the light
"Please don’t die on me," the nurse begged as Porter Stansberry lay in a hospital bed, his heart stopped from years of pushing himself too hard. At his lowest point, he realized that everything had gone wrong, and he was forced to rebuild—not just his health, but his entire life and fortune. After clawing his way out of that abyss, Porter discovered a life-changing investment strategy, one that allowed him to rebuild his wealth far faster and with less risk than he ever imagined. This approach helped him earn enormous returns outside of the volatile stock market, and now he’s sharing it with you. While most won’t believe it’s possible, Porter is asking you to open your mind and consider a new way of investing—one that could transform your financial future, just as it did for him.
U Power Ltd Ordinary Shares - Class A
National Tyre & Wheel Director Increases Shareholding
National Tyre & Wheel: Director Expands Shareholding
Saiheat Ltd Ordinary Shares - Class A
C-LAB Ltd Ordinary Shares
See More Headlines

NDRM Stock Analysis - Frequently Asked Questions

NeuroDerm Ltd. - Ordinary Share (NASDAQ:NDRM) announced its quarterly earnings results on Thursday, May, 11th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.13.

NeuroDerm Ltd. - Ordinary Share (NDRM) raised $45 million in an initial public offering on Friday, November 14th 2014. The company issued 4,500,000 shares at a price of $10.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Oppenheimer and Roth Capital Partners were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroDerm Ltd. - Ordinary Share investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), (KITE) (KITE) and Dynavax Technologies (DVAX).

Company Calendar

Last Earnings
5/11/2017
Today
3/18/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:NDRM
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:NDRM) was last updated on 3/19/2025 by MarketBeat.com Staff
From Our Partners